These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 30219500)

  • 1. Kind and distribution of cutaneous sensation loss in hereditary transthyretin amyloidosis with polyneuropathy.
    Pinto MV; Dyck PJB; Gove LE; McCauley BM; Ackermann EJ; Hughes SG; Waddington-Cruz M; Dyck PJ
    J Neurol Sci; 2018 Nov; 394():78-83. PubMed ID: 30219500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ala97Ser transthyretin amyloidosis-associated polyneuropathy, clinical and neurophysiological profiles in a Thai cohort.
    Pasutharnchat N; Taychargumpoo C; Vorasettakarnkij Y; Amornvit J
    BMC Neurol; 2021 May; 21(1):206. PubMed ID: 34022837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of measures of polyneuropathy impairment in hATTR amyloidosis: From NIS to mNIS + 7.
    Dyck PJB; González-Duarte A; Obici L; Polydefkis M; Wiesman JF; Antonino I; Litchy WJ; Dyck PJ
    J Neurol Sci; 2019 Oct; 405():116424. PubMed ID: 31445300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-L
    Coelho T; Ando Y; Benson MD; Berk JL; Waddington-Cruz M; Dyck PJ; Gillmore JD; Khella SL; Litchy WJ; Obici L; Monteiro C; Tai LJ; Viney NJ; Buchele G; Brambatti M; Jung SW; St L O'Dea L; Tsimikas S; Schneider E; Geary RS; Monia BP; Gertz M
    Neurol Ther; 2021 Jun; 10(1):375-389. PubMed ID: 33638113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective study of a TTR FAP cohort to modify NIS+7 for therapeutic trials.
    Suanprasert N; Berk JL; Benson MD; Dyck PJ; Klein CJ; Gollob JA; Bettencourt BR; Karsten V; Dyck PJ
    J Neurol Sci; 2014 Sep; 344(1-2):121-8. PubMed ID: 25012480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO-TTR trial.
    Waddington-Cruz M; Ackermann EJ; Polydefkis M; Heitner SB; Dyck PJ; Barroso FA; Wang AK; Berk JL; Dyck PJB; Monia BP; Hughes SG; Tai L; Jesse Kwoh T; Jung SW; Coelho T; Benson MD; Gertz MA
    Amyloid; 2018 Sep; 25(3):180-188. PubMed ID: 30169969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 6MWT performance correlates with peripheral neuropathy but not with cardiac involvement in patients with hereditary transthyretin amyloidosis (hATTR).
    Vita GL; Stancanelli C; Gentile L; Barcellona C; Russo M; Di Bella G; Vita G; Mazzeo A
    Neuromuscul Disord; 2019 Mar; 29(3):213-220. PubMed ID: 30718023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Canadian Guidelines for Hereditary Transthyretin Amyloidosis Polyneuropathy Management.
    Alcantara M; Mezei MM; Baker SK; Breiner A; Dhawan P; Fiander A; Fine NM; Hahn C; Katzberg HD; Khayambashi S; Massie R; Matte G; Putko B; Siddiqi Z; Delgado D; Bril V
    Can J Neurol Sci; 2022 Jan; 49(1):7-18. PubMed ID: 33631091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis.
    Benson MD; Waddington-Cruz M; Berk JL; Polydefkis M; Dyck PJ; Wang AK; Planté-Bordeneuve V; Barroso FA; Merlini G; Obici L; Scheinberg M; Brannagan TH; Litchy WJ; Whelan C; Drachman BM; Adams D; Heitner SB; Conceição I; Schmidt HH; Vita G; Campistol JM; Gamez J; Gorevic PD; Gane E; Shah AM; Solomon SD; Monia BP; Hughes SG; Kwoh TJ; McEvoy BW; Jung SW; Baker BF; Ackermann EJ; Gertz MA; Coelho T
    N Engl J Med; 2018 Jul; 379(1):22-31. PubMed ID: 29972757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year update.
    Brannagan TH; Coelho T; Wang AK; Polydefkis MJ; Dyck PJ; Berk JL; Drachman B; Gorevic P; Whelan C; Conceição I; Plante-Bordeneuve V; Merlini G; Obici L; Plana JMC; Gamez J; Kristen AV; Mazzeo A; Gentile L; Narayana A; Olugemo K; Aquino P; Benson MD; Gertz M;
    J Neurol; 2022 Dec; 269(12):6416-6427. PubMed ID: 35908242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis.
    Coelho T; Yarlas A; Waddington-Cruz M; White MK; Sikora Kessler A; Lovley A; Pollock M; Guthrie S; Ackermann EJ; Hughes SG; Karam C; Khella S; Gertz M; Merlini G; Obici L; Schmidt HH; Polydefkis M; Dyck PJB; Brannagan Iii TH; Conceição I; Benson MD; Berk JL
    J Neurol; 2020 Apr; 267(4):1070-1079. PubMed ID: 31853709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Red flags in patients with hereditary transthyretin amyloidosis at diagnosis in a non-endemic area of Spain.
    Silva-Hernández L; Horga Hernández A; Valls Carbó A; Guerrero Sola A; Montalvo-Moraleda MT; Galán Dávila L
    Neurologia (Engl Ed); 2023 Mar; 38(2):87-92. PubMed ID: 36396096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term treatment effects of inotersen on health-related quality of life in patients with hATTR amyloidosis with polyneuropathy: Analysis of the open-label extension of the NEURO-TTR trial.
    Karam C; Brown D; Yang M; Done N; Zhu JJ; Greatsinger A; Bozas A; Vera-Llonch M; Signorovitch J
    Muscle Nerve; 2022 Oct; 66(4):438-446. PubMed ID: 35799473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Late-onset hereditary ATTR V30M amyloidosis with polyneuropathy: Characterization of Brazilian subjects from the THAOS registry.
    Pinto MV; Pinto LF; Dias M; Rosa RS; Mundayat R; Pedrosa RC; Waddington-Cruz M
    J Neurol Sci; 2019 Aug; 403():1-6. PubMed ID: 31163298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rate of neuropathic progression in hereditary transthyretin amyloidosis with polyneuropathy and other peripheral neuropathies: a systematic review and meta-analysis.
    Lin X; Yarlas A; Vera-Llonch M; Baranwal N; Biber J; Brown D; Vogt B; Karam C
    BMC Neurol; 2021 Feb; 21(1):70. PubMed ID: 33579211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early diagnosis in patients with transthyretin familial amyloid polyneuropathy: A comparative study.
    Raya-Cruz M; Buades-Reines J; Gállego-Lezáun C; Ripoll-Vera T; Usón-Martín M; Cisneros-Barroso E
    Med Clin (Barc); 2017 Jan; 148(2):63-66. PubMed ID: 27919414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of quantitative sensation testing of hypoesthesia and hyperalgesia are predictive of diabetic polyneuropathy: a study of three cohorts. Nerve growth factor study group.
    Dyck PJ; Dyck PJ; Larson TS; O'Brien PC; Velosa JA
    Diabetes Care; 2000 Apr; 23(4):510-7. PubMed ID: 10857944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mNIS+7 and lower limb function in inotersen treatment of hereditary transthyretin-mediated amyloidosis.
    Dyck PJB; Kincaid JC; Wiesman JF; Polydefkis M; Litchy WJ; Mauermann ML; Ackermann EJ; Guthrie S; Pollock M; Jung SW; Baker BF; Dyck PJ
    Muscle Nerve; 2020 Oct; 62(4):502-508. PubMed ID: 32654212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of inotersen on Neuropathy Impairment Score in patients with hereditary transthyretin amyloidosis with polyneuropathy.
    Yarlas A; Lovley A; Brown D; Vera-Llonch M; Khella S; Karam C
    BMC Neurol; 2023 Mar; 23(1):108. PubMed ID: 36932361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative sensation and autonomic test abnormalities in transthyretin amyloidosis polyneuropathy.
    Kim DH; Zeldenrust SR; Low PA; Dyck PJ
    Muscle Nerve; 2009 Sep; 40(3):363-70. PubMed ID: 19618439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.